NCT07015697 2026-03-20A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid TumorsDaiichi SankyoPhase 1 Recruiting76 enrolled
NCT06244485 2026-02-04A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid TumorsDaiichi SankyoPhase 1 Recruiting210 enrolled
NCT04042701 2025-11-18DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung CancerDaiichi SankyoPhase 1 Active not recruiting115 enrolled
NCT05765851 2025-05-11A Study of DS-1103a Combination Therapy in Participants With Advanced Solid TumorsDaiichi SankyoPhase 1 Active not recruiting78 enrolled
NCT03523572 2025-01-27Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial CancerDaiichi SankyoPhase 1 Completed86 enrolled 22 charts
NCT02564900 2024-01-22Study of DS-8201a in Subjects With Advanced Solid Malignant TumorsDaiichi SankyoPhase 1 Completed292 enrolled 35 charts 2 FDA
NCT03383692 2023-12-11Study of DS-8201a for Participants With Advanced Solid Malignant TumorsDaiichi SankyoPhase 1 Completed40 enrolled 20 charts
NCT03368196 2022-11-03DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) ProteinDaiichi SankyoPhase 1 Completed12 enrolled 15 charts
NCT03366428 2022-04-12Phase 1 Study to Evaluate the Effect of DS-8201a on the QT/QTc Interval and Pharmacokinetics in HER2-Expressing Breast CancerDaiichi SankyoPhase 1 Completed51 enrolled 14 charts